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Psoriasisa b s t r a c t
Background: IL-20 plays an important role in the inflammatory and hyperproliferative dermatosis of pso-
riasis.
Aim: The aim of the study was to determine whether the IL-20 gene polymorphism, haplotype and serum
level confer pathogenesis of psoriasis.
Subjects and methods: 200 psoriatic patients and 200 controls were genotyped for four IL-20 polymorphic
sites by polymerase chain reaction. Serum levels of IL-20 were measured by ELISA.
Results: Our results demonstrated that polymorphism of IL-120 1380 A/G (adjusted⁄ OR 5.52; (95%
CI = 2.43–12.55) was found to be in association with increased risk of psoriasis while as IL-20–1462 G/A
(adjusted⁄ OR = 0.11 95; (95% CI = 0.03–0.34) was found to be in association with decreased risk of pso-
riasis and IL-20–1053 G/T adjusted⁄ OR 1.99; (95% CI = 0.86–4.64), IL-20–3978 T/C(adjusted⁄ OR = 12.87;
(95% CI = 0.97–79.54) polymorphism does not show any significant association with the risk of psoriasis.
HT4 TG haplotype is associated with decreased risk of psoriasis. Serum IL-20 level significantly increases
in patients, as compared to controls with non-significant correlation between serum IL-20 and psoriasis
severity.
Conclusion: These findings suggest that IL-20 polymorphism have significant role towards the suscepti-
bility of psoriasis in north Indian population. Evaluating the role of IL-20 cytokine in pathogenesis of pso-
riasis will prove helpful for the development of psoriasis management.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Psoriasis is a polygenic cutaneous disorder characterized by
hyperproliferation, differentiation of keratinocytes, and influx of
immune cells into the epidermis [1,2]. The prevalence of psoriasis
has recently been inferred as varying from 0.44 to 2.80% in india
[3]. IL-20 belongs to the IL-10 cytokine family, which also includes
IL-19, IL-22, IL-24, and IL-26 [2,4]. IL-20 is secreted by immune
cells and activated epithelial cells like keratinocytes [5]. The func-
tion of IL-20 might therefore mediate a crosstalk between epithe-
lial cells and tissue-infiltrating immune cells under inflammatory
conditions [6]. IL 20 binds to the receptor expressed on ker-
atinocytes [7]. The exposure of the cells to IL-20 induces STAT3activation which appears to be the initiator of the signal in the epi-
dermal keratinocytes, leading to the development of psoriatic
lesion [6,8]. There is strong evidence that interleukin-20 (IL-20)
has a role in the pathogenesis of cutaneous inflammation and in
psoriasis [9,10]. Genes encoding for the IL-10, IL-19, IL-20 and IL
24 are found within a 200 kb region of chromosome 1, and all com-
prise of IL-10 family cytokine cluster [2,10]. Earlier studies have
presented evidence for an association between IL-10 SNPs with
susceptibility to a numerous autoimmune, infectious and malig-
nant, diseases [11]. Until now, few studies have confirmed that
the IL-20 SNPs contribute to the susceptibility towards psoriasis
[12–14]. In the view of the above findings, IL-20 appears to be
the candidate gene for psoriasis understanding. The present study
was designed to investigate whether the IL-20 polymorphism, hap-
lotype analysis and serum levels may be risk factors for the devel-
opment of psoriasis in north India. To our knowledge no
polymorphism study of IL-20 gene has been reported till now in
north Indian population.
202 A. Wani et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 201–2052. Materials and methods
2.1. Subject recruitment
This hospital based case-control study was conducted after
approval by the ethical committee. The subjects were included
only after they willingly decided to become part of the study,
and filled the consent form. This study was conducted over the
period of fifteen months starting from September 2014 up to
November 2015 and includes 200 clinically diagnosed psoriatic
patients. The inclusion of psoriasis patients was based on the
proper diagnosis which included PASI calculation. Gender,
age (±7 years) and geographically matched healthy subjects were
included as controls in the study.2.2. PASI calculation
Psoriasis Area and Severity Index (PASI) is widely used tool for
the measurement of severity of psoriasis. PASI score was calculated
as described by Langle et al. [15]. The more value of PASI score rep-
resents a greater degree of psoriatic severity [16].2.3. Blood sampling
Five ml of venous blood was taken after taking consent from
each subject and was divided into two portions. 2 ml was taken
in sterile EDTA coated vials for Genomic DNA Extraction and the
remaining was centrifuged at 4000 rpm for 5 min. Serum separated
was stored at 80 C till analysis.2.4. Genomic DNA extraction
Genomic DNA was isolated from the blood samples by using
Phenol-Chloroform method [17] and the isolated DNA was stored
at 20 C for future use.2.5. Genotyping of IL-20
Novel tetra-primer ARMS-PCR method was applied for genotyp-
ing of polymorphisms of IL-20 as prescribed by Kingo et al., [12]
Each PCR reaction was carried out in a total volume of 10 ml con-
taining 100 ng of template DNA, 20 pmol of each inner primer,
20 pmol of each outer primer, optimized concentrations of master
mix. To increase the specificity of a PCR reaction we applied touch-
down cycles: initial denaturation at 95 C for 2 min followed by 10
cycles of 1 min denaturation at 95 C, annealing at 10 C higher
than annealing temperature for 1 min (decreasing by 1 C per
cycle) and extension at 72 C for 1 min.Table 1
Characteristics of study group.
Characteristics
Age: X ± SD
Sex Male
Female
Family History of psoriasis




PASI: X ± SD
PDI: X ± SD3. Results
Two hundred confirmed psoriatic cases and an equal number of
healthy, age and gender matched controls were recruited in this
study. After analyzing the data out of 200 cases recruited in the
present study, 130 (65%) were males and 70 (35%) were females.
It was found that age ranged from 18 to 70 years with mean
38.61 ± 13.713 in the psoriatic patients while in controls, age ran-
ged from 19 to 65 years with mean value of 36.695 ± 11.4765.
Thirty-two (16%) psoriatic patients show the positive family his-
tory for psoriasis. Of all the regions majority of cases numbering
57.5% were from rural areas while as 42.5% are from urban areas.
Body Mass Index (BMI) of psoriatic patients and controls was
26.94 ± 4.17 Kg/m2 and 24.80 ± 4.28 kg/m2 respectively. The mean
value of PASI score for clinical assessment in psoriatic patients was
(10.654 ± 9.09) (Table 1).
The allele frequencies and genotype frequencies of IL20 1053T/
G(rs2981572), IL 20-1380A/G (rs2981573), IL20-1462G/A
(rs2232360) and IL 3978T/C(rs1518108) SNPs in patients and con-
trols are summarized in Tables 2–5 respectively. Genotype distri-
butions for the four analyzed IL-20 gene polymorphisms had no
deviation from Hardy–Weinberg equilibrium. The minor T allele
and TT genotype frequency at position 1053 (rs2981572), was
found higher in cases as compared to that of controls
(OR = 1.091; 95% CI = 0.816–1.458, adjusted⁄ OR = 1.99; 95%
CI = 0.86–4.64 respectively). The difference came out to be statisti-
cally non-significant which confirms that 1053TT genotype is not
associated with risk of psoriasis. Constructed dominant model do
not show any association with the risk of psoriasis. However over-
dominant (adjusted⁄ OR = 2.52; 95% CI = 1.13–5.63) shows associa-
tion of genotypes as a risk factor for psoriasis and recessive models
(adjusted⁄ OR = 0.57; 95% CI = 0.36–0.91) plays a protective role for
psoriasis. Representative gel picture of IL-20-1053 T/G (rs2981572)
gene polymorphism by ARMS PCR as shown in Fig. 1. The fre-
quency of minor G allele and GG genotype at position 1380
(rs2981573) was found higher in cases as compared to that of con-
trols (OR = 3.44; 95% CI = 2.26–5.24, adjusted⁄ OR 5.52; 95%
CI = 2.43–12.55 respectively) which confirms that 1380A/G poly-
morphism is associated with increased risk of psoriasis. The dom-
inant (adjusted⁄ OR = 3.43; 95% CI = 1.88–6.28) and recessive
(Adjusted⁄ OR = 5.52; (95% CI = 2.31–11.83) models show associa-
tion of genotypes as a risk factor for psoriasis. However no such
association has been seen in case of over dominant model. Repre-
sentative gel picture of IL-20-1380 A/G (rs2981573) gene polymor-
phism by ARMS PCR as shown in Fig. 2. The frequency of minor G
allele and GG genotype at position 1462 (rs2232360) was found
higher in controls as compared to that of cases (OR = 0.681; 95%
CI = 0.51–0.90, adjusted⁄ OR = 0.11 95; 95% CI = 0.03–0.34
respectively). The polymorphism of IL-20-1462A/G was found to
be in association with decreased risk of psoriasis. The dominant
(adjusted⁄ OR = 0.46; 95% CI = 0.24–0.86) and recessive (adjusted⁄Cases (%) Controls (%)
38.61 ± 13.71 Years 36.695 ± 11.47 Year
130 (65.00%) 130 (65.00%)
70 (35.00%) 70 (35.00%)
32(16.00%) –
9.88 ± 8.19 Years
115 (57.50%) 115 (57.50%)
85 (42.50%) 85 (42.50%)
26.94 ± 4.17 24.80 ± 4.28
10.654 ± 9.09 –
19.11 ± 6.1081
Table 2
Distribution of genotypes and allele Frequency of IL-20-1053 (rs2981572) Polymorphism in psoriasis cases and controls.
Genotype Cases n (%) Controls n (%) Un adjusted OR (95% CI) Adjusted* OR (95% CI) P value
IL 20-1053G/T
(rs 2981572)
G/G 82 (41.00) 75 (37.50) 1 1
T/G 90 (45.00) 112 (56.00) 0.73 (0.48–1.12) 0.65 (0.40–1.06) 0.18
T/T 28 (14.00) 13 (6.50) 1.97 (0.95–4.08) 1.99 (0.86–4.64) 0.095
Dominant G/G 82 (41.00) 75 (37.50) 1.00 1 0.31
T/G + T/T 118 (59.00) 125 (62.50) 0.86 (0.58–1.29) 0.78 (0.49–1.25)
Recessive G/G + T/G 172(86.00) 187 (93.50) 1.00 1.00 0.02
T/T 28 (14.00) 13 (6.50) 2.34 (1.17–4.67) 2.52 (1.13–5.63)
Overdominant G/G + T/T 110 (55.00) 88 (44.00) 1.00 1 0.016
T/G 90(45.00) 112 (56.00) 0.64 (0.43–0.95) 0.57 (0.36–0.91)
Allele G 254 (63.5) 262 (65.5) 1 0.60
T 146 (36 0.5) 138 (34.5) 1.091 (0.81–1.46)
n = Number of Individuals, Statistically Significant p < 0.05.
* Adjusted OR (95% CI) were obtained when OR was adjusted for age and family history.
Table 3
Distribution of genotypes and allele Frequency of IL-20-1380 A/G (rs 2981573) Polymorphism in psoriasis cases and controls.
Genotype Cases n (%) Controls n (%) Un adjusted OR (95% CI) Adjusted* OR (95% CI) P value
IL 20-1380A/G
(rs 2981573)
A/A 143 (71.50) 176 (88.00) 1 1 –
A/G 17 (8.50) 14 (7.00) 1.49 (0.71–3.14) 1.92 (0.82–4.46) 0.38
G/G 40 (20.00) 10 (5.00) 4.92 (2.38–10.19) 5.52 (2.43–12.55) 0.0001
Dominant A/A 143 (71.50) 176 (88.00) 1.00 1 0.0001
A/G + G/G 57 (28.50) 24 (12.00) 2.92 (1.73–4.94) 3.43 (1.88–6.28)
Recessive A/A + A/G 160 (80.00) 190 (95.00) 1.00 1 0.0001
G/G 40 (20.00) 10(5.00) 4.75 (2.30–9.80) 5.52 (2.31–11.83)
Overdominant A/A + G/G 183 (91.50) 186 (52.50) 1.00 1 0.27
A/G 17 (8.50) 14 (47.50) 1.23 (0.59–2.58) 1.59 (0.69–3.66)
Allele A 303 (75.75) 366 (91.50) 1 0.0001
G 97 (24.25) 34 (8.50) 3.44 (2.26–5.24)
n = Number of Individuals, Statistically Significant p < 0.05.
* Adjusted OR (95%CI) were obtained when OR was adjusted for age and family history.
Table 4
Distribution of genotypes and allele Frequency of IL-20-1462 (rs2232360) Polymorphism in psoriasis cases and controls.
Genotype Cases n (%) Controls n (%) Un adjusted OR (95% CI) Adjusted* OR (95% CI) P value
IL 20-1462 AG
(rs2232360)
A/A 42 (21.00) 25 (12.50) 1 1
A/G 150(75.00) 146 (73.00) 0.61 (0.35–1.05) 0. 52 (0.28–0.99) 0.10
G/G 8(4.00) 29 (14.50) 0.16 (0.07–0.41) 0.11 (0.03–0.34) 0.0001
Dominant A/A 42 (21.00) 25 (12.50) 1.00 1 0.015
A/G + G/G 158 (79.00) 175 (87.50) 0.54 (0.31–0.92) 0.46 (0.24–0.86)
Recessive A/A + A/G 192 (96.00) 171 (85.50) 1.00 1 0.0001
G/G 8 (4.00) 29 (14.50) 0.25 (0.11–0.55) 0.19 (0.07–0.51)
Overdominant A/A + G/G 50(25.00) 54 (27.00) 1.00 1.00 0.8
A/G 150(75.00) 146 (73.00) 1.11 (0.71–1.74) 1.07 (0.63–1.81)
Allele A 234 (58 0.50) 196(49.00) 1 0.0087
G 166 (41.5 0) 204 (51.00) 0.681 (0.51–0.90)
n = Number of Individuals, Statistically Significant p < 0.05.
* Adjusted OR (95%CI) were obtained when OR was adjusted for age and family history.
Table 5
Distribution of genotypes and allele Frequency of IL-20-3978 (rs1518108) Polymorphism in psoriasis cases and controls.
Genotype Cases n (%) Controls n (%) Un adjusted OR (95% CI) Adjusted* OR (95% CI) P value
IL 20-3978T/C
(rs1518108)
T/T 45 (22.50) 46 (23.00) 1 1
T/C 148 (74.00) 153 (76.50) 0.99 (0.62–1.58) 1.11 (0.64–1.95) 0.92
C/C 7(3.50) 1 (0.50) 7.16 (0.85–60.53) 12.87 (0.97–79.54) 0.076
Dominant T/T 45 (22.50) 46 (2.00) 1.00 1 0.49
T/T + C/C 155(77.5) 154 (77.00) 1.03 (0.64–1.64) 1.21 (0.70–2.11)
Recessive T/T + T/C 193(96.50) 199 (99.50) 1.00 1 0.076
C/C 7 (3.50) 1(0.50) 7.22(0.88–59.22) 12.80 (0.95–80.50)
Overdominant T/T + C/C 52 (26.00) 47(23.50) 1.00 1 0.84
T/C 148 (74.00) 153 (76.50) 0.87 (0.55–1.35) 0.95(0.55–1.62)
Allele T 238(59.50) 245(61.25) 1 0.66
C 162(40.50) 155(38.75) 1.07 (0.81–1.42)
n = Number of Individuals, Statistically Significant p < 0.05.
* Adjusted OR (95% CI) were obtained when OR was adjusted for age and family history.
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Fig. 1. Representative gel picture of IL-20-1053T/G (rs2981572) gene polymor-
phism by ARMS PCR.
Fig. 2. Representative gel picture of IL-20-1380A/G (rs2981573) gene polymor-
phism by ARMS PCR.
Fig. 3. Representative gel picture of IL-20-1462G/A (rs2232360) gene polymor-
phism by ARMS PCR.
Fig. 4. Representative gel picture of IL-20-3978T/C (rs1518108) gene polymor-
phism by ARMS PCR.
Table 6
Possible Haplotype Frequencies of IL 20 gene in cases and controls.
Haplotye 1053 1462 Cases (%)
HT 1 G A 34.50
HT 2 G G 29.00
HT 3 T A 24.00
HT 4 T G 12.00
Statistically Significant p < 0.05.
204 A. Wani et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 201–205OR = 0.19; 95% CI = 0.07–0.51) models also show significant
association of genotypes with decreased risk of psoriasis. However,
overdominant model does not show any association with the risk
of psoriasis. Representative gel picture of IL-20-1462G/A
(rs2232360) gene polymorphism by ARMS PCR as shown in
Fig. 3. The minor C allele and CC genotype frequency at position
3978 (rs1518108) was found higher in cases as compared to that
of controls (OR = 1.07; 95% CI = 0.81–1.42, adjusted⁄ OR = 12.87;
95% CI = 0.97–79.54 respectively) but the difference was not
statistically significant. The dominant (adjusted⁄ OR = 1.21;
95% CI = 0.70–2.11) overdominant (adjusted⁄ OR = 12.80; 95%
CI = 0.95–80.50) and recessive (adjusted⁄ OR = 0.95; 95%
CI = 0.55–1.62) models do not show any association of allele as a
risk factor for psoriasis. Representative gel picture of IL-20-
3978T/C (rs1518108) gene polymorphism by ARMS PCR as shown
in Fig. 4.
Haplotype frequencies of psoriasis patients and controls are
summarized in Table 6. The pair wise LD Matrix demonstrated that
the nearly complete L.D (D > 0 < 1 (D, between 0.30 and 0.50)
existed between the polymorphism of position 1053 and 1462
within the IL-20 gene. We excluded SNP 1380 rs2981573 from
the haplotype analyses because the frequency of its minor allele
was lower than 10%. The presence of four haplotypes with a fre-
quency of 1 was estimated. The haplotypes accounted for 95%
of all haplotypes in pooled samples. The frequency of HT4 haplo-
type was increased in controls than cases which reflects the pro-
tective role of haplotype HT4 TG. (OR = 0.44; 95% CI = 0.24–0.79)
in psoriasis which confirms its association with decreased risk of
psoriasis. IL-20 serum level in Psoriatic patients are highly elevated
(95 ± 25.51) as compared to controls (44.995 ± 927) respectively
(p = 0.005). We observed a non significant correlation between
IL-20 serum level and disease severity (p = 0.38) (Table 7).4. Discussion
The present report is the first demonstration of the association
between IL-20 polymorphism and psoriasis in north Indian popula-
tion. Psoriasis subjects have sharply demarcated, erythematous
and elevated skin lesions with marked silvery scales. These clinical
features are determined by the thickened epidermis with hyper-
proliferation and abnormal differentiation of keratinocytes due to
increased mitotic activity in the basal layer with the loss of the
granular layer. Vascular hyperplasia and a rich immune cell infil-
trate in the dermis complete the histological aspect of psoriatic
plaques [4,18,19]. The evidence for the role of IL 20 is that the over-
expression of IL-20 in transgenic mices induces lesions similar to
those seen in psoriatic subjects [10]. Blumberg et al. had seen that
IL-20 transgenic mice skin showed hyperkeratosis, thickened epi-
dermis and proliferation in the suprabasal layer resembling human
psoriatic abnormalities. Casteligans et al. have observed similar
histological changes in human psoriatic skin [20]. These changes
in skin appear to be caused by circulating IL-20, because even mice
expressing transgene in liver were similarly affected [10]. In psori-
asis the IL-20 polymorphism was associated with different form of
diseases such as early onset familial and sporadic diseases [12].
The present study investigates four polymorphism within theControl (%) OR 95 CI P
34.00 1
31.00 0.58 (0.31–1.09) 0.093
14.00 1.47 (0.72–3.00) 0.29
20.00 0.44 (0.24–0.79) 0.0068
Table 7
Correlation between serum levels of Psoriasis patients and control and its relation with severity.
Serum Cytokine Level Cases (2 0 0) Controls (2 0 0) r p value
IL 20 (pg/m): Mean ± SD 95 ± 25.51 44.995 ± 9. 27 0.23 0.005
Range (70–120) (30–50)
Serum level With PASI 0.0208 0.38
IL 20 (pg/m): Mean ± SD PASI Mean ± SD
95 ± 25.51 10.65 ± 9.09
Statistically Significant p < 0.05.
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IL-20 1380A>G polymorphism is associated with the increased risk
of psoriasis. Our result substantiate the early findings [12] while as
few findings show decreased risk as in palmoplantar psoriasis and
Ulcerative colitis [21–23]. On the other hand IL-20 1462A>G is
associated with decreased risk of psoriasis while as IL-20
3978T>C does not show any association. Kingo et al. found no asso-
ciation of both IL-20 1462A>G and IL 20 3978T>C with psoriasis
[12]. In our study Control group had significantly increased fre-
quency of HT4GA haplotype (OR = 0.4495; 95%CI = 0.24–0.79)
which reflects its protective role in psoriasis. However, GAA has
been found to be associated with plaque and palmoplantar psoria-
sis [12,21]. This suggests that IL-20 gene cluster might harbour a
common genetic factor for all types of psoriasis. To validate this
hypothesis further studies with large subjects should be done. IL-
20 serum level in Psoriatic patients are highly elevated in cases
as compared to controls. Kunz et al. also confirms that there is
increased level of IL-20 in the lesional skin of psoriasis as well as
the blood [24] [25]. Wolks et al. correlates IL-20 levels with PASI
score of patients with lower significance [26]. We observed a non
significant correlation between IL-20 serum level and disease
severity which is in line with earlier studies [26,25]. In conclusion
IL-20 gene and IL-20 HT GGA haplotype has been found to be asso-
ciated with increased risk of psoriasis. Serum Level of IL-20 was
also significantly increased in psoriatic subjects on comparison to
control. It can be concluded that highlighting the role of cytokines
in the pathogenesis of psoriasis may play pivotal role for the devel-
opment of data base, maintenance and resolution of lesions. The
outcome of this study provides first evidence regarding IL-20 gene
and psoriasis in north Indian population. Further research with
large samples should be done in order to determine the exact
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